Gracevit® is the commercial brand name of Sitafloxacin Tablets, developed by Shionogi. It is an oral broad-spectrum fluoroquinolone antibacterial agent. It inhibits bacterial DNA gyrase and topoisomerase IV to block bacterial replication, exerting strong bactericidal activity against gram-positive, gram-negative and…
Orkedia® is the commercial brand name of Evocalcet Tablets, developed by Kyowa Kirin of Japan. It is a new-generation oral calcimimetic agent. It activates calcium-sensing receptors on parathyroid gland cells to suppress parathyroid hormone secretion and parathyroid cell proliferation, lowering…
Somatuline Autogel® is the commercial brand name of Lanreotide Acetate Sustained-release Injection, developed by Ipsen. It is a pre-filled long-acting gel-type somatostatin analog. It suppresses excess secretion of growth hormone, IGF-1 and gastrointestinal hormones, relieves clinical symptoms of hormone-secreting tumors…
Sandostatin LAR® is the commercial brand name of Octreotide Acetate Microspheres for Injection, developed by Novartis. It is a long-acting somatostatin analogue microsphere preparation. It inhibits the secretion of growth hormone, glucagon and insulin, relieves symptoms caused by hormone-secreting neuroendocrine…
Staquis® is the commercial brand name of Crisaborole Ointment, developed by Pfizer. It is a topical phosphodiesterase 4 (PDE4) inhibitor for external cutaneous use. It blocks inflammatory signaling pathways in skin lesions to relieve erythema, pruritus and dryness of atopic…
ZENON® is the commercial brand name of Rosuvastatin Calcium and Ezetimibe Tablets (I), developed by Sanofi. It is a fixed-dose oral compound lipid-regulating preparation. Rosuvastatin inhibits hepatic cholesterol synthesis while ezetimibe blocks intestinal cholesterol absorption, producing synergistic lipid-lowering effects to…
Leqvio® is the commercial brand name of Inclisiran Sodium Injection, developed by Novartis. It is a long-acting small interfering RNA therapeutic agent targeting PCSK9 synthesis. It inhibits hepatic PCSK9 production persistently, elevates low-density lipoprotein receptor levels on liver cells and…
Repatha® is the commercial brand name of Evolocumab Injection, developed by Amgen Manufacturing Limited. It is a fully human monoclonal antibody targeting PCSK9; it blocks the binding between PCSK9 and hepatic LDL receptors to elevate LDL receptor quantity, significantly lowering…
Praluent® is the commercial brand name of Alirocumab Injection, developed by Sanofi. It is a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9). It blocks the binding of PCSK9 to low-density lipoprotein receptors, increasing hepatic LDL receptor…
Entresto® is the commercial brand name of Sacubitril Valsartan Sodium Tablets, developed by Novartis. It is an oral dual-acting cardiovascular agent combining neprilysin inhibitor and angiotensin II receptor antagonist. It enhances endogenous natriuretic peptide levels while blocking angiotensin receptors, exerting…